Business

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered ...

articleAspire Biopharma Holdings, Inc.April 16, 20264/company/aspire-biopharma-inc/news/aspire-biopharma-has-entered-into-a-letter-of-intent-to-acquire-a-leading-global-automotive-supplier-with-a-100-year-history-and-dollar200m-in-2025-revenue
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.","length":652,"tagName":"p"},{"type":"text","content":"The proposed acquisition represents a transformative milestone for Aspire and positions the Company to grow into a diversified, high-revenue enterprise.","length":152,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"DCS delivered more than $20M in Adjusted EBITDA on $200M+ Revenue for FY2025 (unaudited).","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"DCS provides a technical proprietary portfolio of over 275 different parts and 310 patents serving more than 150 vehicle platforms across most major automotive OEMs.","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Lakewood and existing management bring over 200 years of collective automotive experience with major OEMs, Suppliers, and related Industrial Companies.","length":151,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":405,"olType":false},{"type":"text","content":"Key Transaction Terms","length":21,"tagName":"p"},{"type":"text","content":"Subject to completion of due diligence, including completion and review of an audit of DCS's financial statements under U.S. GAAP, Aspire is expected to acquire 100% of DCS for a total purchase price of $30 million paid in cash.","length":232,"tagName":"p"},{"type":"text","content":"About DCS: A Leader in Next-Gen Mobility","length":40,"tagName":"p"},{"type":"text","content":"DCS is a tier-one supplier specializing in vehicle electrification, safety, and human-machine interface (HMI) systems. For the fiscal year ended December 31, 2025 (unaudited), DCS generated revenue of more than $200 million, net income of more than $17 million and Adjusted EBITDA of more than $22 millio...

More updates from Aspire Biopharma Holdings, Inc.

BiopharmaThe CompanyControl Systemsdelivery technologyhuman-machine interface